ZA200711169B - Oral solid pharmaceutical formulation of the tubulin inhibitor Indibulin - Google Patents

Oral solid pharmaceutical formulation of the tubulin inhibitor Indibulin

Info

Publication number
ZA200711169B
ZA200711169B ZA200711169A ZA200711169A ZA200711169B ZA 200711169 B ZA200711169 B ZA 200711169B ZA 200711169 A ZA200711169 A ZA 200711169A ZA 200711169 A ZA200711169 A ZA 200711169A ZA 200711169 B ZA200711169 B ZA 200711169B
Authority
ZA
South Africa
Prior art keywords
indibulin
pharmaceutical formulation
solid pharmaceutical
oral solid
tubulin inhibitor
Prior art date
Application number
ZA200711169A
Other languages
English (en)
Inventor
Roessler Berthold
Raab Gerhard
Reissmann Thomas
Original Assignee
Ziopharm Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ziopharm Oncology Inc filed Critical Ziopharm Oncology Inc
Publication of ZA200711169B publication Critical patent/ZA200711169B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200711169A 2005-06-14 2007-12-20 Oral solid pharmaceutical formulation of the tubulin inhibitor Indibulin ZA200711169B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/151,459 US20060280787A1 (en) 2005-06-14 2005-06-14 Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof

Publications (1)

Publication Number Publication Date
ZA200711169B true ZA200711169B (en) 2009-01-28

Family

ID=37524356

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200711169A ZA200711169B (en) 2005-06-14 2007-12-20 Oral solid pharmaceutical formulation of the tubulin inhibitor Indibulin

Country Status (21)

Country Link
US (1) US20060280787A1 (xx)
EP (1) EP1922061B8 (xx)
JP (2) JP2008543798A (xx)
KR (1) KR20080045110A (xx)
CN (1) CN101277681B (xx)
AT (1) ATE417603T1 (xx)
AU (1) AU2006257428B2 (xx)
BR (1) BRPI0613139A2 (xx)
CA (1) CA2612288A1 (xx)
DE (1) DE602006004365D1 (xx)
DK (1) DK1922061T3 (xx)
ES (1) ES2319929T3 (xx)
HK (1) HK1120739A1 (xx)
IL (1) IL188164A (xx)
MX (1) MX2007016081A (xx)
NO (1) NO20076509L (xx)
NZ (1) NZ564927A (xx)
PT (1) PT1922061E (xx)
RU (1) RU2008100236A (xx)
WO (1) WO2006133835A2 (xx)
ZA (1) ZA200711169B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE19946301A1 (de) 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
WO2008066807A1 (en) * 2006-11-28 2008-06-05 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
TW201113266A (en) * 2009-09-02 2011-04-16 Ziopharm Oncology Inc Pharmaceutical formulations for indibulin

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2745785A (en) * 1952-10-29 1956-05-15 American Home Prod Therapeutic composition comprising tabular nu, nu'-dibenzylethylenediamine di-penicillin, and process for preparing same
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4798846A (en) * 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US5023271A (en) * 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
IL86211A (en) * 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
US5707634A (en) * 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US5188937A (en) * 1989-04-06 1993-02-23 Becton, Dickinson And Company Layered sandwich assay method for chlamydia and materials therefor
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
IE67187B1 (en) * 1990-06-15 1996-03-06 Merck & Co Inc A crystallization method to improve crystal structure and size
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5389263A (en) * 1992-05-20 1995-02-14 Phasex Corporation Gas anti-solvent recrystallization and application for the separation and subsequent processing of RDX and HMX
SE9202128D0 (sv) * 1992-07-09 1992-07-09 Astra Ab Precipitation of one or more active compounds in situ
US5417956A (en) * 1992-08-18 1995-05-23 Worcester Polytechnic Institute Preparation of nanophase solid state materials
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
DE4305003A1 (de) * 1993-02-18 1994-08-25 Knoll Ag Verfahren zur Herstellung kolloidaler wäßriger Lösungen schwer löslicher Wirkstoffe
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
FR2703927B1 (fr) * 1993-04-13 1995-07-13 Coletica Utilisation d'une réaction de transacylation entre un polysaccharide estérifié et une polyamine pour former en milieu aqueux une membrane au moins en surface de particules gélifiées.
DE69435141D1 (de) * 1993-07-19 2008-10-30 Angiotech Pharm Inc Anti-angiogene Mittel und Verfahren zu deren Verwendung
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
AU687093B2 (en) * 1994-09-27 1998-02-19 Nycomed Imaging As Contrast agent
US5720551A (en) * 1994-10-28 1998-02-24 Shechter; Tal Forming emulsions
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5605785A (en) * 1995-03-28 1997-02-25 Eastman Kodak Company Annealing processes for nanocrystallization of amorphous dispersions
CA2216919C (en) * 1995-03-28 2007-09-18 Fidia Advanced Biopolymers Srl Nanospheres comprising a biocompatible polysaccharide
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
CA2253260A1 (en) * 1996-05-02 1997-11-13 Taisho Pharmaceutical Co., Ltd. Suspension of sparingly water-soluble acidic drug
US6063808A (en) * 1996-07-01 2000-05-16 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (S,S)-glycopyrrolate
WO1998007414A1 (en) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
US6344271B1 (en) * 1998-11-06 2002-02-05 Nanoenergy Corporation Materials and products using nanostructured non-stoichiometric substances
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
WO1998014180A1 (en) * 1996-10-03 1998-04-09 Dmitri Kirpotin Hydrophilic microparticles and methods to prepare same
US5874111A (en) * 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
IT1292142B1 (it) * 1997-06-12 1999-01-25 Maria Rosa Gasco Composizione farmaceutica in forma di microparticelle lipidiche solide atte alla somministrazione parenterale
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
DE69813254T2 (de) * 1997-08-05 2004-04-01 Microfluidics International Corp., Newton Hochdruck mischer-reaktor mit mehrfachströmen
US5834032A (en) * 1997-08-11 1998-11-10 Song; Moon K. Compositions and methods for treating diabetes
US6225329B1 (en) * 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US6337092B1 (en) * 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
ATE233549T1 (de) * 1998-06-19 2003-03-15 Skyepharma Canada Inc Neues verfahren zur herstellung von partikeln wasserunlöslicher komponenten im grössenbereich bis 2000 nm
FR2780901B1 (fr) * 1998-07-09 2000-09-29 Coletica Particules, en particulier micro- ou nanoparticules de monosaccharides et oligosaccharides reticules, leurs procedes de preparation et compositions cosmetiques, pharmaceutiques ou alimentaires en contenant
US6238677B1 (en) * 1998-08-18 2001-05-29 The United States Of America As Represented By The Secretary Of Agriculture Starch microcapsules for delivery of active agents
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6365191B1 (en) * 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6045826A (en) * 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US20020048610A1 (en) * 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
EP1276465B1 (en) * 2000-04-20 2014-03-12 Jagotec AG Improved water-insoluble drug particle process
US6561402B2 (en) * 2000-05-16 2003-05-13 Black & Decker Inc. Ambidextrous drill holster
IT1320209B1 (it) * 2000-06-21 2003-11-26 Marzoli Spa Gruppo per compattare un fascio di fibre tessili stirato in unfilatoio.
KR100867392B1 (ko) * 2000-08-15 2008-11-06 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 마이크로입자
ES2326209T3 (es) * 2000-10-27 2009-10-05 Baxter Healthcare S.A. Produccion de microesferas.
EP1364643A4 (en) * 2000-12-01 2009-07-15 Kyowa Hakko Kogyo Kk COMPOSITION WITH IMPROVED ORAL SOLUBILITY OR ABSORBABILITY
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20040022861A1 (en) * 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
EP1258891A2 (en) * 2001-05-17 2002-11-20 Shipley Co. L.L.C. Resistors
US20030044333A1 (en) * 2001-06-13 2003-03-06 Johan Wanselin Device for an autoclave
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
DE10152306A1 (de) * 2001-10-26 2003-07-24 Asta Medica Ag 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften
DE60309300T3 (de) * 2002-03-20 2011-02-24 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von angiogeneseinhibitoren
US6521923B1 (en) * 2002-05-25 2003-02-18 Sirenza Microdevices, Inc. Microwave field effect transistor structure on silicon carbide substrate
US7211588B2 (en) * 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
WO2006002887A1 (en) * 2004-06-29 2006-01-12 Baxter International Inc. Aqueous drink solution of indibulin (d-24851) and an organic acid
JP2008519036A (ja) * 2004-11-08 2008-06-05 バクスター・インターナショナル・インコーポレイテッド チューブリン阻害化合物のナノ粒子組成物

Also Published As

Publication number Publication date
PT1922061E (pt) 2009-03-24
DK1922061T3 (da) 2009-04-20
AU2006257428B2 (en) 2012-03-22
JP2013151574A (ja) 2013-08-08
IL188164A (en) 2010-11-30
IL188164A0 (en) 2008-03-20
DE602006004365D1 (de) 2009-01-29
NZ564927A (en) 2010-12-24
BRPI0613139A2 (pt) 2010-12-21
MX2007016081A (es) 2008-03-10
CA2612288A1 (en) 2006-12-21
EP1922061A2 (en) 2008-05-21
JP2008543798A (ja) 2008-12-04
EP1922061B8 (en) 2010-09-08
US20060280787A1 (en) 2006-12-14
ES2319929T3 (es) 2009-05-14
EP1922061B1 (en) 2008-12-17
WO2006133835A2 (en) 2006-12-21
KR20080045110A (ko) 2008-05-22
CN101277681B (zh) 2013-03-20
NO20076509L (no) 2008-02-27
AU2006257428A1 (en) 2006-12-21
HK1120739A1 (en) 2009-04-09
RU2008100236A (ru) 2009-07-20
WO2006133835A3 (en) 2007-07-19
ATE417603T1 (de) 2009-01-15
CN101277681A (zh) 2008-10-01
WO2006133835A8 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
NZ573555A (en) Nanoparticulate posaconazole formulations
ZA200711169B (en) Oral solid pharmaceutical formulation of the tubulin inhibitor Indibulin
UY38044A (es) Composiciones farmacéuticas sólidas que comprenden fenofibrato en nanopartículas
HK1077195A1 (en) Modafinil pharmaceutical compositions
WO2007053197A3 (en) Nanoparticulate acetaminophen formulations
WO2007116954A3 (en) Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
IL175072A (en) Controlled-release sterile injectable aripiprazole formulation containing 1 to 10 micron average-sized once or twice-a-month, including freeze-dried formulation, preparation, and use for the treatment of schizophrenia
WO2008008733A3 (en) Nanoparticulate sorafenib formulations
BRPI0517662A (pt) partìculas de ramipril estabilizadas revestidas, processo para o revestimento de ramipril, composição farmacêutica oral sólida, métodos para evitar e tratar distúrbios cardiovasculares, e, processo para fabricar uma composição farmacêutica
WO2005025535A8 (en) Methods for preparing pharmaceutical compositions
CA2430318A1 (en) Powder formulation and method for producing the same
HUP0202781A2 (hu) Béta-karbolin szemcsés formája, ezt tartalmazó gyógyszerkészítmények, előállításaik és alkalmazásuk
WO2006041843A3 (en) Pharmaceutical dosage form comprising meloxicam
IL172704A (en) Pharmaceuticals containing salinosporamide compound and use of this compound for the preparation of a cancer drug
UA95088C2 (ru) Композиция, которая содержит наночастички связанные с биосовместимым полимером противоракового агента и снижает аллопецию при химиотерапии, способ ее получения
SG162811A1 (en) Nanoparticulate and controlled release compositions comprising aryl- heterocyclic compounds
WO2005123086A3 (en) Ziprasidone dosage form
GB0319797D0 (en) Particle size reduction of poorly soluble drugs
EP1622808A4 (en) FLUIDIZATION OF PARTICLES FOR SEPARATION IN ORAL TO PHARMACEUTICAL PRODUCTS TO BE ADMITTED
WO2007146943A3 (en) Nanoparticulate kinase inhibitor formulations
WO2009044380A3 (en) Formulations containing orlistat particles having controlled particle size
JP2006028171A (ja) 生薬末含有錠剤
WO2008001294A3 (en) High dose oral pharmaceutical compositions of artemether and lumefantrine
WO2007106111A3 (en) Nanoparticulate and controlled release compositions comprising nilvadipine
PL1518551T3 (pl) Stała postać dawki zawierająca kofeinę